Mosaic ImmunoEngineering, trading under the ticker OTCMKTS:CPMV, is a biotechnology company focused on the design and development of next-generation vaccines and immunotherapies. The company’s proprietary platform employs engineered virus-like particles and self-assembling mosaic nanoparticles to present a broad array of antigens, with the goal of eliciting robust and durable immune responses. By leveraging structure-based antigen design and advanced bioinformatics, Mosaic ImmunoEngineering aims to address both established and emerging infectious diseases, as well as certain forms of cancer.
The company’s product pipeline encompasses a range of preclinical candidates targeting respiratory viruses, including influenza and respiratory syncytial virus (RSV), as well as novel coronaviruses. In addition, Mosaic ImmunoEngineering is advancing immuno-oncology programs that harness its particle-based platform to stimulate anti-tumor immunity. Research collaborations with academic institutions and strategic partnerships with biopharmaceutical companies support the company’s efforts to optimize antigen presentation, improve vaccine potency, and streamline manufacturing processes for scalable production.
Headquartered in the United States, Mosaic ImmunoEngineering maintains research operations that integrate immunology, protein engineering, and nanotechnology. The company’s R&D team works closely with government agencies and non-profit foundations to secure funding for early-stage development, while its business development group explores licensing agreements and co-development opportunities both domestically and internationally. By combining scientific rigor with collaborative partnerships, Mosaic ImmunoEngineering seeks to accelerate the translation of its vaccine and therapeutic candidates from laboratory discovery to clinical evaluation.
Founded in the late 2010s as a spin-out from leading academic laboratories, Mosaic ImmunoEngineering is led by a management team with deep experience in biotechnology and vaccine development. The company’s executive leadership includes professionals who have held senior positions at established biopharma firms and academic research centers, bringing expertise in regulatory strategy, clinical development, and manufacturing scale-up. Through a commitment to innovation in antigen design and nanoparticle assembly, Mosaic ImmunoEngineering aims to deliver transformative solutions that enhance global public health and address unmet medical needs.
AI Generated. May Contain Errors.
Free CPMV Stock Alerts